Blog

May 26, 2023

Why Racial & Ethnic Diversity in Clinical Oncology Trials Matters

When clinical trials fail to include racial and ethnic diversity into medical research, it can be harmful for large segments of the population. There is a real-world need for clinical oncology trials to adequately represent diverse racial and ethnic groups to better reflect the populations that are most likely to benefit from a drug.

January 23, 2023

ASCO GI Reaction - SUNLIGHT

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study

January 23, 2023

ASCO GI Reaction - NAPOLI-3

NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)

January 23, 2023

ASCO GI Reaction - Neo AEGIS

Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis

January 22, 2023

ASCO GI Reaction - INFINITY

INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC)

January 22, 2023

ASCO GI Reaction - SPOTLIGHT

Zolbetuximab + mFOLFOX6 as first-line treatment for patients with claudin-18.2+ / HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: Primary results from phase 3 SPOTLIGHT study

December 14, 2022

ASH22 Reaction - TRIANGLE

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

December 14, 2022

ESMO-IO Reaction - KRYSTAL-7 and KRYSTAL-1

Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

December 13, 2022

ASH 22 Reactions - GEM-CESAR

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

December 12, 2022

SABCS Reactions - DESTINY-Breast02

Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02

December 12, 2022

SABCS Reactions - DESTINY-Breast03

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

December 11, 2022

SABCS Reactions - P2RIGHT Choice

Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy

December 9, 2022

SABCS Reactions - MonarchE

Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

September 16, 2022

Breast Cancer through LARVOL Eyes

This October, we are recognizing Breast Cancer Awareness Month with three very different takes on breast cancer from our organization and the Tigers who make us who we are.

ESMO Reactions: COSMIC-313

Phase III study ofcabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) inpreviously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediateor poor risk (COSMIC-313)

ESMO Reactions: TROPiCS-2

Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) inpatients with HR+/HER2- metastatic breast cancer.

ESMO Reactions: S1801

Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)

ESMO Reactions: CodeBreaK 200

Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study.

ESMO Reactions: ADAURA

Osimertinib as adjuvant therapy in patients(pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

September 21, 2021

ESMO 2021 Clinical Panel: Melanoma

Tune into the discussion among top KOLs around Melanoma data presented at this year's ESMO virtual congress.

September 20, 2021

ESMO 2021 Clinical Panel: GU

Tune into the discussion among top KOLs around GU data presented at this year's ESMO virtual congress.

September 17, 2021

IASLC 2021 World Conference Clinical Panel: Lung Cancer

Watch KOL Insights on Abstracts released during the IASLC 2021 World Conference on Lung Cancer.

August 26, 2021

How to Tell the Difference Between Insights and Observations in Medical Affairs

What makes an “observation” an “insight” in the world of Medical Affairs? This is the question tackled by Medical Affairs professionals on this month’s Elevate podcast from the Medical Affairs Professionals Society (MAPS).

August 16, 2021

LARVOL CEO Experiments with One Year in the Metaverse

"The future of business is in the metaverse," Larvol says. "And we want to explore every angle of its use for workplace collaboration and for the future of cancer research and drug development."

July 26, 2021

The Virtual Reality: Tips for Making the Most of Conference Attendance in 2021 and Beyond

What will conferences look like for MSLs throughout 2021, 2022, and beyond? And how should MSLs prepare to make the most of the changing reality?

June 10, 2021

ASCO Clinical Panel Series: GU Cancer

Watch KOL Insights on GU Cancer Abstracts released during the ASCO Annual Meeting 2021

June 10, 2021

ASCO Clinical Panel Series on Breast, Melanoma, Gastrointestinal, Lung, Genitourinary Cancers, and DLBCL

Watch KOL Insights on Cancer Abstracts released during the ASCO Annual Meeting 2021

ASCO Clinical Panel Series: Lung Cancer

Watch KOL Insights on Lung Cancer Abstracts released during the ASCO Annual Meeting 2021

LARVOL VIEW Top 100 Most Influential Oncologists on Twitter 2021

LARVOL VIEW Top 100 is a curated list of the most influential Digital Opinion Leaders (DOLs) in oncology on Twitter. Our methodology selects and ranks DOLs based on online influence, offline activity, and the opinions of other verified oncologists.

ASCO Clinical Panel Series: Breast Cancer

Watch KOL Insights on Breast Cancer Abstracts released during the ASCO Annual Meeting 2021

ASCO Clinical Panel Series: DLBCL

Watch KOL Insights on DLBCL Abstracts released during the ASCO Annual Meeting 2021

LARVOL Launches Platform to Curate Historical and Active Immuno-Oncology Clinical Trial Data in a Digital Dashboard

CLIN's launch marks an exciting next step in the innovative work LARVOL is doing to streamline the work of oncologists and researchers

June 7, 2021

ASCO Clinical Panel Series: GI Cancer

Watch KOL Insights on GI Cancer Abstracts released during the ASCO Annual Meeting 2021

June 7, 2021

ASCO Clinical Panel Series: Melanoma

Get Expert Insights on Melanoma Abstracts released during the ASCO Annual Meeting 2021

May 24, 2021

A Medical Affairs Professional’s Guide to Attending #ASCO21

In order to get the most out of your conference attendance, you will need to have a clear plan in place.

May 20, 2021

LARVOL Utilizes ASCO 2021 Virtual Meeting to Share Clinical Research and Engage Oncology Thought Leaders

LARVOL announces their clinical research poster, a VR-based oncologist event, and a clinical panel series during ASCO 2021

May 17, 2021

The Top 100 Oncology Conferences for 2021

Our team of experts put together a list of the top 100 oncology conferences happening in 2021, organized in an easy-to-reference calendar view.

May 11, 2021

Spatial Spotlights LARVOL’s #VRFirst, #RemoteAlways Culture

In our VR offices, co-workers who are thousands of miles apart can finally meet via Spatial’s 3D avatar system.

May 5, 2021

LARVOL Tigers Celebrate the Strength of Mothers Everywhere

This Mother’s Day, we celebrate mothers everywhere.

April 28, 2021

LARVOL Expands Commitment to Virtual Reality Workspace for Global Team

Headset distribution solidifies intent to remain #1 VR-first company

AACR Clinical Panel Series: Genitourinary Cancer

Watch KOL Insights on Genitourinary Cancer Abstracts released during the AACR Annual Meeting 2021

AACR Clinical Panel Series on Breast, Hematologic Malignancies, Gastrointestinal, Lung, and Genitourinary Cancers

Watch KOL Insights on Cancer Abstracts released during the AACR Annual Meeting 2021

AACR Clinical Panel Series: Gastrointestinal Cancer

Watch KOL Insights on Gastrointestinal Cancer Abstracts released during the AACR Annual Meeting 2021

AACR Clinical Panel Series: Breast Cancer

Watch KOL Insights on Breast Cancer Abstracts released during the AACR Annual Meeting 2021

Support for India: COVID-19 Relief

To help those interested in advocating for support for India's efforts to control the spread of COVID-19, we’ve gathered these instructions and suggested language for outreach to US Representatives and Senators.

AACR Clinical Panel Series: Lung Cancer

Watch KOL Insights on Lung Cancer Abstracts released during the AACR Annual Meeting 2021

AACR Clinical Panel Series: Hematologic Malignancies

Watch KOL Insights on Hematologic Malignancies Abstracts released during the AACR Annual Meeting 2021

April 13, 2021

LARVOL Launches the First Cancer-Focused Social Listening Platform for Pharma and Oncology

Curated comments and sentiment from verified oncologists empower pharma marketing, competitive intelligence, and medical affairs teams to make informed decisions

April 12, 2021

3 Emerging Uses of Social Media beyond Passive Listening for MSLs and Medical Affairs

Read this blog to explore how MSLs and medical affairs can use social media to achieve professional growth and do much more

April 6, 2021

LARVOL to be Featured at ScaleUp 360° Competitive Intelligence in Pharma & Life Science Virtual Conference

Coincides with launch of first social listening and sentiment analysis platform allowing researchers and pharma developers to tune into the cancer conversation with verified oncologists on Twitter

Infographics

April 5, 2021

[Infographic] 46% MSLs report Building New Relationships with KOLs as a Primary Challenge

Our insightful infographic breaks down the challenges being faced by MSLs because of no in-person meetings with KOLs

March 29, 2021

Zoom In: 10 Tips to Make Virtual KOL Meetings more Engaging and Productive

Read this article first published on The MSL Journal to uncover tips that will help you maintain and even strengthen your relationships with KOLs with engaging virtual meetings.

March 15, 2021

Overcoming the Void of In-Person KOL Engagements

Read this summary of insights from our latest webinar with the MSL Society to discuss the experience of the MSL community nearly a year to the day since the COVID-19 pandemic shut down their ability to meet with KOLs in person.

February 23, 2021

LARVOL Appoints New Vice President, Global Sales

LARVOL announced the addition of Mark Lagunowich to their Executive Team. As Vice President, Global Sales, Lagunowich brings over 30 years of experience in the life science industry.

February 14, 2021

Discussion on the Top Abstracts from ASCO-Genitourinary (ASCO-GU) Conference 2021

Watch a panel of experts discuss the practice-changing potential of ASCO GU 2021's top abstracts on the standard of care.

February 5, 2021

Unlocking the Power of Predictive Biomarker Databases

Take a deep dive into the current predictive biomarker landscape—and what the future holds.

December 22, 2020

8 Ways VUCA has evolved the value proposition in the current times and 5 key takeaways for MSLs

The Covid-19 pandemic has once again brought VUCA in focus. Read our blog understand the evolving value proposition for MSLs.

December 15, 2020

Discover the latest advancements in the field of predictive biomarkers with LARVOL's Sabrina Bellisario and Dr. Mark Gramling

Learn more about “Google for cancer” Veri and the latest technologies in the field of predictive biomarkers in our blog here.

Infographics

November 30, 2020

[Infographic] How do you compare with your peers? Social Listening of KOLs by MSLs

Discover meaningful and relevant insights on KOL monitoring by MSLs in our infographic.

November 30, 2020

Top 3 Trends for MSLs to Increase KOL Engagement during the Covid-19 Pandemic

Read our blog to know more about the ways you can increase KOL engagement during the pandemic.